Alpha 2.0
Login Register
» Authors » A de Bartolomeis

A de Bartolomeis

Explore the profile of A de Bartolomeis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 22
Citations 743
Followers 0
Related Specialties
Neurology
Psychiatry
Molecular Biology
Top 10 Co-Authors
F Iasevoli
D Pickar
M Fornaro
D De Berardis
E F Buonaguro
J N Crawley
W C Eckelman
A Breier
S Novello
G Perna
Published In
Psychiatry Res
Brain Res Mol Brain Res
J Affect Disord
Neurochem Int
Ann N Y Acad Sci
Affiliations
Soon will be listed here.
Recent Articles
1.
Treating depression in patients with borderline personality disorder: clinical clues on the use of antidepressants
Tomasetti C, Autullo G, Ballerini A, de Bartolomeis A, DellOsso B, Fiorentini A, et al.
Ann Gen Psychiatry . 2024 May; 23(1):21. PMID: 38816843
Personality disorders (PD) are described as enduring patterns of markedly deviant and pervasive inner experiences and behaviors, with onset in adolescence, which lead to severe distress or impairment. Patients suffering...
2.
Clinical features associated with early drop-out among outpatients with unipolar and bipolar depression
Fornaro M, Novello S, Fusco A, Anastasia A, De Prisco M, Mondin A, et al.
J Psychiatr Res . 2020 Oct; 136:522-528. PMID: 33127073
Drop-out from follow-up visits carries significant burden for people diagnosed with depression. The present study assesses multiple clinical moderators of drop-out among depressed outpatients. We retrospectively followed-up 131 outpatients over...
3.
The impact of affective temperaments on clinical and functional outcome of Bipolar I patients that initiated or changed pharmacological treatment for mania
Perugi G, Cesari D, Vannucchi G, Maccariello G, Barbuti M, de Bartolomeis A, et al.
Psychiatry Res . 2018 Jan; 261:473-480. PMID: 29360052
Background: Affective temperaments have been shown to impact on the clinical manifestations and the course of bipolar disorder. We investigated their influence on clinical features and functional outcome of manic...
4.
Predictors of hospitalization length of stay among re-admitted treatment-resistant Bipolar Disorder inpatients
Fornaro M, Iasevoli F, Novello S, Fusco A, Anastasia A, De Berardis D, et al.
J Affect Disord . 2017 Dec; 228:118-124. PMID: 29245092
Background: Hospitalization accounts for significant health care resource utilization for treatment-resistant Bipolar Disorder (BD), especially among frequent users of acute inpatient psychiatric units. Appraisal of the clinical features and predictive...
5.
Dopamine transporter (DAT) genetic hypofunction in mice produces alterations consistent with ADHD but not schizophrenia or bipolar disorder
Mereu M, Contarini G, Buonaguro E, Latte G, Manago F, Iasevoli F, et al.
Neuropharmacology . 2017 Apr; 121:179-194. PMID: 28454982
ADHD, schizophrenia and bipolar disorder are psychiatric diseases with a strong genetic component which share dopaminergic alterations. Dopamine transporter (DAT) genetics might be potentially implicated in all these disorders. However,...
6.
Does the "" Lose its Shine Over the Time? Assessment of Loss of Lithium Response in a Preliminary Sample of Bipolar Disorder Outpatients
Fornaro M, Stubbs B, De Berardis D, Iasevoli F, Solmi M, Veronese N, et al.
Clin Pract Epidemiol Ment Health . 2017 Feb; 12:142-157. PMID: 28217142
Background: Though often perceived as a "silver bullet" treatment for bipolar disorder (BD), lithium has seldom reported to lose its efficacy over the time. Objective: The aim of the present...
7.
An update of safety of clinically used atypical antipsychotics
Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, et al.
Expert Opin Drug Saf . 2016 Jun; 15(10):1329-47. PMID: 27347638
Introduction: The atypical antipsychotic (APs) drugs have become the most widely used agents to treat a variety of psychoses because of their superiority with regard to safety and tolerability profile...
8.
Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice
Guida F, Luongo L, Marmo F, Romano R, Iannotta M, Napolitano F, et al.
Mol Brain . 2015 Aug; 8:47. PMID: 26260027
Background: Enhanced supraspinal glutamate levels following nerve injury are associated with pathophysiological mechanisms responsible for neuropathic pain. Chronic pain can interfere with specific brain areas involved in glutamate-dependent neuropsychological processes,...
9.
A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice
Errico F, DArgenio V, Sforazzini F, Iasevoli F, Squillace M, Guerri G, et al.
Transl Psychiatry . 2015 Feb; 5:e512. PMID: 25689573
Increasing evidence points to a role for dysfunctional glutamate N-methyl-D-aspartate receptor (NMDAR) neurotransmission in schizophrenia. D-aspartate is an atypical amino acid that activates NMDARs through binding to the glutamate site...
10.
Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins
de Bartolomeis A, Buonaguro E, Iasevoli F
Psychopharmacology (Berl) . 2012 Nov; 225(1):1-19. PMID: 23179966
The physical and functional interactions between serotonin-glutamate and serotonin-dopamine signaling have been suggested to be involved in psychosis pathophysiology and are supposed to be relevant for antipsychotic treatment. Type II...